Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

被引：0

作者：

Fisher, Benjamin A. ^{[1
]}

Mariette, Xavier ^{[2
]}

Papas, Athena S. ^{[3
]}

Grader-Beck, Thomas ^{[4
]}

Bootsma, Hendrika ^{[5
]}

Ng, Wan-Fai ^{[6
]}

Van Daele, Paul ^{[7
]}

Finzel, Stephanie ^{[8
]}

Elgueta, Sergio ^{[9
]}

Hermann, Josef ^{[10
]}

McCoy, Sara ^{[11
]}

Bookman, Arthur ^{[12
]}

Sopala, Monika ^{[13
]}

Luo, Wen-Lin ^{[14
]}

Scheurer, Cornelia ^{[13
]}

Hueber, Wolfgang ^{[13
]}

机构：

[1] Univ Birmingham, Birmingham, W Midlands, England

[2] Univ Paris Saclay, Le Kremlin Bicetre, France

[3] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA

[4] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA

[5] Univ Med Ctr Groningen, Dept Rheumatol, Groningen, Netherlands

[6] Newcastle Tyne Hosp NHS Fdn Trust, NIHR Newcastle Clin Res Facil, Newcastle Upon Tyne, Tyne & Wear, England

[7] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[8] Univ Freiburg, Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany

[9] Clin Res Chile SpA, Biomed Res Ctr, Valdivia, Chile

[10] Med Univ Graz, Dept Internal Med, Div Rheumatol & Immunol, Graz, Austria

[11] Univ Wisconsin, Sch Med & Publ Hlth, Middleton, WI USA

[12] Toronto Western Hosp, Toronto, ON, Canada

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1634

引用

页码：3242 / 3244

页数：3

共 50 条

[21] A randomized, placebo-controlled, dose-ranging study to deltermine the efficacy, safety, and tolerability of perampanel, a selective amPA receptor antagonist, in patients with advanced Parkinson's disease
Oertel, Wolfgang
Eggert, Karla
Squillacote, David
NEUROLOGY, 2008, 70 (11) : A423 - A424
[22] Cardiovascular Safety Profile of Ensifentrine in Patients with COPD: Results from Two Four-Week, Dose-Ranging, Randomized, Placebo-Controlled Trials
Rickard, K.
Bengtsson, T.
Rheault, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
[23] Key learnings and the informed design of a randomized, placebo-controlled, dose-ranging phase 2b study to evaluate the efficacy of tezepelumab in moderate-to-severe Atopic Dermatitis
Komjathy, S.
Griffiths, J.
Parnes, J. R.
ALLERGY, 2020, 75 : 194 - 195
[24] Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Ritchlin, Christopher T.
Kavanaugh, Arthur
Merola, Joseph F.
Schett, Georg
Scher, Jose U.
Warren, Richard B.
Gottlieb, Alice B.
Assudani, Deepak
Bedford-Rice, Kathy
Coarse, Jason
Ink, Barbara
McInnes, Iain B.
LANCET, 2020, 395 (10222): : 427 - 440
[25] EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
Van der Heijde, D.
Gensler, L. S.
Deodhar, A.
Baraliakos, X.
Poddubnyy, D.
Kivitz, A.
Farmer, M. K.
Baeten, D.
Goldammer, N.
Coarse, J.
Oortgiesen, M.
Dougados, M.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 68 - 69
[26] EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY
Xu, D.
Zhang, S.
Huang, C.
Huang, C.
Qin, L.
Li, X.
Chen, M.
Liu, X.
Liu, Y.
Li, Z.
Hu, J.
Bao, C.
Wei, W.
Tian, J.
Duan, X.
Van Vollenhoven, R.
Fang, J.
Zeng, X.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 94 - 95
[27] Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Merrill, Joan T.
Wallace, Daniel J.
Wax, Stephen
Kao, Amy
Fraser, Patricia
Chin, Wai
Isenberg, David A.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[28] A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose-ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis
Waldbaum, Arthur S.
Schwebke, Jane R.
Paull, Jeremy R. A.
Price, Clare F.
Edmondson, Stephanie R.
Castellarnau, Alex
McCloud, Philip
Kinghorn, George R.
PLOS ONE, 2020, 15 (05):
[29] Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial
D'Haens, Geert R.
Panaccione, Remo
Higgins, Peter
Colombel, Jean-Frederic
Feagan, Brian G.
Moscariello, Michele
Chan, Gary
Healey, Paul J.
Niezychowski, Wojciech
Wang, Wenjin
Marren, Amy
Maller, Eric
GASTROENTEROLOGY, 2016, 150 (04) : S183 - S183
[30] EFFICACY OF NISOLDIPINE IN STABLE ANGINA - RESULTS OF A MULTICENTER, PLACEBO-CONTROLLED DOSE-RANGING AND RANDOMIZED DOUBLE-BLIND-STUDY
DIBIANCO, R
GLASSER, SP
SMITH, V
THADANI, U
CIRCULATION, 1985, 72 (04) : 275 - 275

← 1 2 3 4 5 →